Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Small Lymphocytic Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (831
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
Non-Hodgkin’s Lymphoma (831
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
›
Associations
(98)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
Chr del(11q)
Small Lymphocytic Lymphoma
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: B - Late Trials
SOHO 2022 - 6 days (New B)
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6d
zanubrutinib
Sensitive: B - Late Trials
SOHO 2022 - 6 days
zanubrutinib
Sensitive
:
B
SOHO 2022 - 6 days - (New B)
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
rituximab + ibrutinib
Sensitive: A1 - Approval
rituximab + ibrutinib
Sensitive
:
A1
rituximab + ibrutinib
Sensitive: A1 - Approval
rituximab + ibrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A1 - Approval
duvelisib
Sensitive
:
A1
duvelisib
Sensitive: A1 - Approval
duvelisib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
PCR
Sensitive: A2 - Guideline
PCR
Sensitive
:
A2
PCR
Sensitive: A2 - Guideline
PCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
FCR
Sensitive: A2 - Guideline
FCR
Sensitive
:
A2
FCR
Sensitive: A2 - Guideline
FCR
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
ofatumumab
Sensitive: A2 - Guideline
ofatumumab
Sensitive
:
A2
ofatumumab
Sensitive: A2 - Guideline
ofatumumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
ofatumumab
Sensitive: A2 - Guideline
ofatumumab
Sensitive
:
A2
ofatumumab
Sensitive: A2 - Guideline
ofatumumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
